Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
The Repertoire partnership is Lilly’s second immunology play of the year, after the acquistion of Ventyx in early January for a pipeline of NLRP3 assets.
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026 Read More »
